Adjusted cumulative incidence of grade III-IV acute GVHD for 8/8 matched vs 7/8 HLA-C with AAS 116 vs 7/8 HLA-C without AAS 116. (A) Adjusted cumulative incidence of grade III-IV acute GVHD at 100 days: (1) 8/8 = 21%; (2) 7/8 without HLA-C AAS 116 = 25%; and (3) 7/8 with HLA-C AAS 116 = 32%. P value for comparisons: (2 vs 1) P = .071; (3 vs 1) P < .0001; (3 vs 2) P = .0088. Adjusted variables: disease stage, graft type, Karnofsky score, patient age, sex match, disease, GVHD prophylaxis, conditioning regimen, in vivo T-cell depletion, year of transplant. (B) Adjusted cumulative incidence of TRM for 8/8 matched vs 7/8 HLA-C with AAS 99 vs 7/8 HLA-C without AAS 99. Adjusted cumulative incidence of TRM for 8/8 matched vs 7/8 HLA-C with AAS 99 vs 7/8 HLA-C without AAS 99 at 1 year: (1) 8/8 = 26%; (2) 7/8 without HLA-C AAS 99 = 31%; and (3) 7/8 with HLA-C AAS 99 = 42%. P value for comparisons: (2 vs 1) P = .012; (3 vs 1) P < .0001; (3 vs 2) P = .00035. Adjusted variables: CMV match, disease, disease stage, donor age, donor race, patient age, graft type, KPS, GVHD prophylaxis, conditioning regimen, interval from diagnosis to transplant, year of transplant. (C) Adjusted cumulative incidence of chronic GVHD for 8/8 matched vs 7/8 HLA-B with AAS 9 vs 7/8 HLA-B without AAS 9. Adjusted cumulative incidence of chronic GVHD for 8/8 matched vs 7/8 HLA-B with AAS 9 vs 7/8 HLA-B without AAS 9 at 2 years: (1) 8/8 = 48%; (2) 7/8 without HLA-B AAS 9 = 40%; and (3) 7/8 with HLA-B AAS 9 = 64%. P value for comparisons: (2 vs 1) P = .0056; (3 vs 1) P = .023; (3 vs 2) P = .0012. Adjusted variables: in vivo T-cell depletion, patient age, sex match, disease, graft type, GVHD prophylaxis, CMV match, conditioning regimen, year of transplant.